Schedule Dispatches

This is an early notification of the changes to be announced in the Update to the Pharmaceutical Schedule.

The full Update is available as a PDF(external link)

The changes will be published in the online Schedule around the 23^rd of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz

December 2025 Dispatch

New Listings

• Cefalexin cap 250 mg (Cefalexin Lupin) (p’code 2712148) and cap 500 mg (Cefalexin Sandoz) (p’code 2712628)
• Covid-19 vaccine (Comirnaty (LP.8.1)) – Xpharm and access criteria apply
  • inj 3 mcg SARS-CoV-2 spike protein (mRNA) LP.8.1 per 0.3 ml, 0.48 ml multi-dose vial; infant vaccine, yellow cap (p’code 2717107)
  • inj 10 mcg SARS-CoV-2 spike protein (mRNA) LP.8.1 per 0.3 ml, 0.48 ml single-dose vial; paediatric vaccine, light blue cap (p’code 2717115)
  • inj 30 mcg SARS-CoV-2 spike protein (mRNA) LP.8.1 per 0.3 ml, pre-filled syringe; adult vaccine (p’code 2717123)
• Docusate sodium with sennosides (Solax) tab 50 mg with sennosides 8 mg (p’code 2712172)
• Entrectinib (Rozlytrek) cap 200 mg – Special Authority – Retail pharmacy (p’code 2599929)
• Ethinyloestradiol with norethisterone (Norimin) tab 35 mcg with norethisterone 500 mcg and 7 inert tab, 112 tab pack – Up to 112 tab available on a PSO (p’code 2636077)
• Faricimab (Vabysmo) inj 120 mg per ml, 0.24 ml vial – Special Authority – Retail pharmacy (p’code 2666715)
• Fulvestrant (Fulvestrant EVER Pharma) inj 50 mg per ml, 5 ml prefilled syringe – Retail pharmacy-Specialist – Special Authority (p’code 2663139)
• Heparin sodium (Wockhardt) inj 10 iu per ml, 5 ml ampoule (flushing solution) – s29 and wastage claimable (p’code 2717840)
• Insulin pump with algorithm (Tandem t:slim X2 with Control-IQ+) min basal rate 0.1 U/h – Special Authority – Retail pharmacy, maximum of 1 dev per prescription, only on a prescription and maximum of 1 insulin pump per patient each four year period (p’code 2714213)
• Isoniazid with rifampicin (Rifamazid) tab 100 mg with rifampicin 150 mg – Retail pharmacy-Specialist, no patient co-payment payable, s29 and wastage claimable (p’code 2718243)
• Methylphenidate hydrochloride (Methylphenidate Sandoz XR) tab modified-release 18 mg (p’code 2711176), tab modified-release 27 mg (p’code 2711184), tab modified-release 36 mg (p’code 2711192) and tab modified-release 54 mg (p’code 2711206) – Special Authority – Retail pharmacy, only on a controlled drug form and safety medicine; prescriber may determine dispensing frequency
• Ocrelizumab (Ocrevus SC) inj 40 mg per ml, 23 ml vial – Special Authority – Retail pharmacy (p’code 2717441)
• Oxycodone hydrochloride (Rosemont) oral liq 1 mg per ml, 250 ml – only on a controlled drug form, no patient co-payment payable, safety medicine; prescriber may determine dispensing frequency and wastage claimable (p’code 2717239)
• Pertuzumab with trastuzumab (Phesgo) inj 600 mg with trastuzumab 600 mg, 10 ml vial (p’code 2649373) and inj 1,200 mg with trastuzumab 600 mg, 15 ml vial (p’code 2649381) – PCT only – Special Authority
• Pharmacy services (BSF Estradiol TDP Mylan) brand switch fee – may only be claimed once per patient (p’code 2717573 )
• Potassium chloride (Span-K) tab long-acting 600 mg (8 mmol) (p’code 2717700)
• Somatropin (Omnitrope) (Omnitrope AU) inj 5 mg cartridge – Special Authority – Retail pharmacy and s29 (p’code 2648415)
• Sunitinib (Sunitinib Rex) cap 50 mg – Special Authority – Retail pharmacy (p’code 2675498)
• Vancomycin (Vancomycin Viatris) inj 500 mg vial – Subsidy by endorsement (p’code 2696282)

Changes to restrictions, chemical names and presentations

• Aflibercept (Eylea) inj 40 mg per ml, 0.1 ml vial – amended Special Authority criteria
• Budesonide (Budesonide Te Arai) cap modified-release 3 mg – amended Special Authority criteria
• Combined Oral Contraceptives – removal of Special Authority criteria
• Continuous glucose monitor (interoperable) sensor (9) and transmitter (Dexcom G6), sensor (Dexcom G7) and sensor (Freestyle Libre 3 Plus) – amended Special Authority criteria
• Continuous glucose monitor (standalone) sensor (Dexcom ONE+), sensor (Freestyle Libre 2 Plus) and sensor (Freestyle Libre 2) – amended Special Authority criteria
• Crizotinib (Xalkori) cap 200 mg and 250 mg – amended Special Authority criteria
• Dabrafenib (Tafinlar) cap 50 mg and 75 mg – amended Special Authority criteria
• Ethinyloestradiol with norethisterone (Norimin) tab 35 mcg with norethisterone 500 mcg and 7 inert tab – amended PSO quantity
• Febuxostat (Febuxostat (Teva)) tab 80 mg and 120 mg – amended Special Authority criteria
• Ferrous fumarate (Ferro-tab) tab 200 mg (65.7 mg elemental) – amended presentation description
• Hypoplastic and Haemolytic – amended Special Authority criteria
• Insulin Pump Consumables – amended Special Authority criteria
• Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists – amended Special Authority criteria
• Methylphenidate hydrochloride tab immediate-release 5 mg, 10 mg and 20 mg (Rubifen), tab immediate-release 10 mg (Ritalin), tab sustained-release 20 mg (Rubifen SR), tab extended-release 18 mg, 27 mg, 36 mg and 54 mg (Methylphenidate ER – Teva) and tab modified-release 18 mg, 27 mg, 36 mg and 54 mg (Methylphenidate Sandoz XR) – amended Special Authority criteria
• Obinutuzumab inj 25 mg per ml, 40 ml vial (Gazyva) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
• Oestradiol (Estradiol TDP Mylan and Estradot) patch 25 mcg, 50 mcg, 75 mcg and 100 mcg per day – addition of brand switch fee
• Pembrolizumab inj 25 mg per ml, 4 ml vial (Keytruda) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
• Progestogen-only Contraceptives – removal of Special Authority criteria
• Rituximab (mabthera) inj 100 mg per 10 ml vial and inj 500 mg per 50 ml vial (Mabthera) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
• Trametinib (Mekinist) tab 0.5 mg and 2 mg – amended Special Authority criteria

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Citalopram hydrobromide	Tab 20 mg	Celapram
Methylphenidate hydrochloride	Tab extended-release 18 mg, 27 mg, 36 mg and 54 mg	Methylphenidate ER – Teva

Decreased subsidy

Chemical	Presentation	Fully subsidised brands
Buprenorphine with naloxone	Tab sublingual 8 mg with naloxone 2 mg	Buprenorphine Naloxone BNM
Denosumab	Inj 60 mg per 1 ml prefilled syringe Inj 120 mg per 1.7 ml vial	Prolia Xgeva
Mitomycin C	Inj 20 mg vial Inj 1 mg for ECP	Teva Baxter
Ocrelizumab	Inj 30 mg per ml, 10 ml vial	Ocrevus
Pantoprazole	Tab EC 20 mg and 40 mg	Panzop Relief
Tranexamic acid	Tab 500 mg	Mercury Pharma
Vinorelbine	Inj 10 mg per ml, 5 ml vial	Vinorelbine Ebewe